Cargando…

Where are we in 2021 with heart failure with reduced ejection fraction?—current outlook and expectations from new promising clinical trials

Guideline-directed optimal medical therapy is a well-established therapy in treating patients with heart failure with reduced ejection fraction (HFrEF). Despite clear recommendations, the prognosis in this group of patients is still poor with high mortality. After publishing results of the PARADIGM-...

Descripción completa

Detalles Bibliográficos
Autores principales: Dębska-Kozłowska, Agnieszka, Książczyk, Marcin, Lelonek, Małgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898246/
https://www.ncbi.nlm.nih.gov/pubmed/34050489
http://dx.doi.org/10.1007/s10741-021-10120-x
_version_ 1784663606389899264
author Dębska-Kozłowska, Agnieszka
Książczyk, Marcin
Lelonek, Małgorzata
author_facet Dębska-Kozłowska, Agnieszka
Książczyk, Marcin
Lelonek, Małgorzata
author_sort Dębska-Kozłowska, Agnieszka
collection PubMed
description Guideline-directed optimal medical therapy is a well-established therapy in treating patients with heart failure with reduced ejection fraction (HFrEF). Despite clear recommendations, the prognosis in this group of patients is still poor with high mortality. After publishing results of the PARADIGM-HF trial (Prospective Comparison of ARNI—Angiotensin Receptor/Neprilysin Inhibitors—with ACEI—Angiotensin-Converting Enzyme Inhibitor—to Determine Impact on Global Mortality and Morbidity in Heart Failure) clinical investigators accelerated their research. Recently, many new trials have been designed to evaluate the efficacy and safety of promising management, taking into account heterogeneity of population with chronic HFrEF. Determining target doses still poses the biggest problem in standard pharmacotherapy. Implementation of new substances for the HFrEF therapy makes it possible to formulate simple rules of treatment—in most cases, administering a dose of drug in one tablet provides a faster therapeutic effect. The aim of this article is to summarize current knowledge on recently announced findings on novel molecules and to propose a new revolutionary and individualised approach to treatment of HFrEF patients.
format Online
Article
Text
id pubmed-8898246
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-88982462022-03-08 Where are we in 2021 with heart failure with reduced ejection fraction?—current outlook and expectations from new promising clinical trials Dębska-Kozłowska, Agnieszka Książczyk, Marcin Lelonek, Małgorzata Heart Fail Rev Article Guideline-directed optimal medical therapy is a well-established therapy in treating patients with heart failure with reduced ejection fraction (HFrEF). Despite clear recommendations, the prognosis in this group of patients is still poor with high mortality. After publishing results of the PARADIGM-HF trial (Prospective Comparison of ARNI—Angiotensin Receptor/Neprilysin Inhibitors—with ACEI—Angiotensin-Converting Enzyme Inhibitor—to Determine Impact on Global Mortality and Morbidity in Heart Failure) clinical investigators accelerated their research. Recently, many new trials have been designed to evaluate the efficacy and safety of promising management, taking into account heterogeneity of population with chronic HFrEF. Determining target doses still poses the biggest problem in standard pharmacotherapy. Implementation of new substances for the HFrEF therapy makes it possible to formulate simple rules of treatment—in most cases, administering a dose of drug in one tablet provides a faster therapeutic effect. The aim of this article is to summarize current knowledge on recently announced findings on novel molecules and to propose a new revolutionary and individualised approach to treatment of HFrEF patients. Springer US 2021-05-29 2022 /pmc/articles/PMC8898246/ /pubmed/34050489 http://dx.doi.org/10.1007/s10741-021-10120-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Dębska-Kozłowska, Agnieszka
Książczyk, Marcin
Lelonek, Małgorzata
Where are we in 2021 with heart failure with reduced ejection fraction?—current outlook and expectations from new promising clinical trials
title Where are we in 2021 with heart failure with reduced ejection fraction?—current outlook and expectations from new promising clinical trials
title_full Where are we in 2021 with heart failure with reduced ejection fraction?—current outlook and expectations from new promising clinical trials
title_fullStr Where are we in 2021 with heart failure with reduced ejection fraction?—current outlook and expectations from new promising clinical trials
title_full_unstemmed Where are we in 2021 with heart failure with reduced ejection fraction?—current outlook and expectations from new promising clinical trials
title_short Where are we in 2021 with heart failure with reduced ejection fraction?—current outlook and expectations from new promising clinical trials
title_sort where are we in 2021 with heart failure with reduced ejection fraction?—current outlook and expectations from new promising clinical trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898246/
https://www.ncbi.nlm.nih.gov/pubmed/34050489
http://dx.doi.org/10.1007/s10741-021-10120-x
work_keys_str_mv AT debskakozłowskaagnieszka wherearewein2021withheartfailurewithreducedejectionfractioncurrentoutlookandexpectationsfromnewpromisingclinicaltrials
AT ksiazczykmarcin wherearewein2021withheartfailurewithreducedejectionfractioncurrentoutlookandexpectationsfromnewpromisingclinicaltrials
AT lelonekmałgorzata wherearewein2021withheartfailurewithreducedejectionfractioncurrentoutlookandexpectationsfromnewpromisingclinicaltrials